comparemela.com

Latest Breaking News On - Douglasa treco - Page 4 : comparemela.com

Inozyme Pharma Slips 9% After Updates To Rare Disease Program

Shares of Inozyme Pharma, Inc. (INZY) are slipping over 9% on Wednesday morning after updates to rare disease program. INZY is currently trading at $5.60, down $0.

United statesInozyme pharmaDouglasa trecoPaediatric committeeInozyme pharma incDrug administrationEuropean medicines agency

Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of

- Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned ENERGY-3 pivotal trial in pediatric patients -

United statesDouglasa trecoMatt peraInozyme pharmaStefan rileyExchange commissionDrug administrationCorporate communicationsEuropean medicines agencyInozyme pharma incPaediatric committeePlanned pivotal trialPediatric patientsPrimary endpointsRadiographic global impressionInvestor relations

Inozyme Pharma to Present at the Jefferies Healthcare Conference

Inozyme Pharma to Present at the Jefferies Healthcare Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDouglasa trecoInozyme pharmaInozyme pharmastefan rileySmithsolvematt peraInozyme pharma incCorporate communicationsJefferies healthcare conferenceInvestor relations

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesStefan rileyYves sabbaghDouglasa trecoInozyme pharmaMatt peraKurt gunterExchange commissionEuropean medicines agencyDevelopment rd expensesInozyme pharma incEuropean congressEuropean calcified tissue societyCorporate communicationsPediatric investigational planFinancial guidance

Alchemab Appoints Young T Kwon as Chief Executive Officer

Press release content from Business Wire. The AP news staff was not involved in its creation.

United kingdomMassachusetts institute of technologyUnited statesHarvard universityPhouman ashrafianOlivia cavlanYoungt kwonDouglasa trecoCorporate developmentMomenta pharmaceuticalsTechnology venturesChief financialOperating officerChief executive officerBusiness officerAdvanced technology ventures

vimarsana © 2020. All Rights Reserved.